Print（PDF/135KB） May 13, 2025 Finances

Announcement of Reduction in Executive Remuneration

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) is improving its performance in the fiscal year 2024 by promoting the expansion of existing product businesses and implementing fundamental structural reforms, including early retirement programs. However, considering the current management situation for rebuilding, the Company announced today that the Company will reduce the remuneration of director as follows.

1) Scope of reduction:

Representative Director, President and CEO 10% of base remuneration

2) Period of reduction of the base remuneration:

From July 2025 to June 2026 (12 months)